OncoMethylome Sciences Reinforces U.S. Presence with Key Executive Appointments
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - September 28, 2010 - OncoMethylome Sciences SA
(Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) today announced the
appointments of Dr. Melissa A. Thompson as Vice President Regulatory Affairs and
Quality Assurance, and of Mr. Christopher (Chris) Thibodeau as Vice President
Commercial Operations.
Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said: "With extensive
experience in the molecular diagnostics space in the U.S., Melissa and Chris
will be instrumental in expanding our presence in the U.S. market. They will
both play a key role in developing and executing our new strategy, providing
invaluable knowledge of the regulatory and commercialization processes. "
Melissa A. Thompson, PhD, MBA, CT (ASCP), VP Regulatory Affairs & Quality
Assurance
Melissa has more than 25 years of experience in the pharmaceutical, medical
device, and molecular diagnostics industries. She has provided extensive
consultative services in diagnostics to leading companies such as Johnson &
Johnson, Wyeth, Inverness, and Affymetrix, as well start-ups like Signature
Genomic Laboratories, Prognomix, Allegro Diagnostics, and ExonHit Therapeutics.
She has fostered multiple products through U.S. Food and Drug Administration
approval, and has additional background in clinical research and clinical trial
design.
Melissa Thompson holds a Ph.D. in Organizational Management from Concordia
University and an MBA from Temple University, Philadelphia, PA.
Christopher Thibodeau, VP Commercial Operations
Chris brings over 15 years of sales, marketing and commercial leadership
experience in the diagnostics arena. As Vice President Commercial Operations, he
is responsible for developing and executing OncoMethylome's key strategic sales
& marketing and business development initiatives. Prior to joining OncoMethylome
he served as Senior Director of Marketing at Agendia Inc., Vice President of
Sales and Marketing for Numira Biosciences, National Director of Sales US LABS
(an industry leader in cancer diagnostic and genomic testing services); and a
number of sales and marketing management roles at Ventana Medical.
Chris Thibodeau holds a BSc degree from the East Stroudsburg University in
Pennsylvania and studied French at the Faculté des Lettres in Nancy, France.
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that
commercializes and develops cancer-screening tests to assist physicians in
detecting and treating cancer early. The company's tests are based on
proprietary gene methylation technology invented at Johns Hopkins University and
are designed to aid the physician detect early stages of cancer development,
predict a patient's response to drug therapy, and predict the likelihood of
cancer recurrence. OncoMethylome Sciences collaborates with leading cancer
research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of
commercial and collaborative partnerships with LabCorp, Schering-Plough,
GlaxoSmithKline Biologicals, Millipore Corporation's BioScience Division, Roche,
Merck KGaA and Qiagen.
For more information:
Dr. Jan Groen
CEO
+32 4.364.20.70 office
IR(at)oncomethylome.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of OncoMethylome and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different.
[HUG#1447065]
2010-09-28 Melissa and Chris ENG:
http://hugin.info/137314/R/1447065/389878.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OncoMethylome Sciences via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 28.09.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 43110
Anzahl Zeichen: 0
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OncoMethylome Sciences Reinforces U.S. Presence with Key Executive Appointments"
steht unter der journalistisch-redaktionellen Verantwortung von
OncoMethylome Sciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
